Big Pharma’s Legal Bill To Take Hit From Pay-For-Delay Ruling
Law360, New York (June 17, 2013, 8:08 PM EDT) -- The U.S. Supreme Court’s ruling Monday requiring stepped-up scrutiny of so-called pay-for-delay deals will force the pharmaceutical industry to spend more money litigating patent suits and devising settlements that won’t be viewed as anti-competitive, experts say.
Under the decision Monday, settlements involving pay-for-delay arrangements, also known as reverse payments, will likely face scrutiny on a number of factors: Whether and how soon the generic drug comes on the market before patent expiration. How much money is involved, relative to future litigation costs. Whether the cash represents compensation for other services, such as marketing of a drug product or supplying of active...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!